Shares of this cell therapies biotech are set to double, says Baird
Shares of biotech company bluebird bio should double in the coming year, thanks to its treatments for sickle cell disease, a genetic blood disease and a rare genetic brain condition, according to Baird. The Wall Street firm initiated coverage of the stock on Monday with an outperform rating and $10 price target, which implies 104% upside from Monday's close.
mountain bluebird bio's year-to-date performance Meanwhile, its launch of Zynteglo, approved in August 2022 for the treatment of transfusion-dependent beta-thalassemia , should also beat analysts' expectations, he said. The company's management said in January that 40 patients had initiated benefits verification for Zynteglo during the last three months of 2022.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Latest ‘Demon Slayer’ Makes $10 Million, But No ‘Mugen Train’ – Specialty Box OfficeAniplex and Crunchyroll of America’s Demon Slayer: Kimetsu no Yaiba – To the Swordsmith Village grossed $10.1 million this weekend in 1,780 theaters. That’s a fourth place finish at the…
Weiterlesen »
Sask. bringing in $10 a day childcare across province by AprilSaskatchewan is set to cap childcare fees at $10 per day beginning in April, leveraging federal dollars to meet affordability targets.
Weiterlesen »
Company Lays Off 8,000 While Paying Matthew McConaughey $10 Million a YearSalesforce, the firm co-helmed by the definitely not Hawaiian Marc Benioff, is the latest in a slew of tech giants to lay off thousands of employees.
Weiterlesen »
Vice owes nearly $10 million to IT firm Wipro, court filing allegesVice owes nearly $10 million to tech consultancy Wipro, a new court filing alleges, as multiple vendors chase fees from the troubled media giant
Weiterlesen »